<p>中國人壽 (02628.HK) +1.280 (+4.672%) 空頭頭寸 $497.98M; 比率 30.304% 今天開盤上漲 4.01%，一度達到 HKD29.18。目前交易價格為 HKD28.84，上漲 5.26%，成交量為 3845.31 萬股，涉及金額為 11.07 億港元。</p>
<p>在昨日市場收盤後，中國人壽公佈了第一季度業績。歸屬於母公司股東的淨利潤為人民幣 195.05 億元，同比下降 32.3%，基本每股收益為人民幣 0.69。在此期間，營業收入同比下降 15.3%，為人民幣 932.91 億元。總保費收入同比增長 1.1%，達到人民幣 3584.78 億元。新業務價值激增 75.5%。</p>
<p>摩根大通表示，新業務價值的強勁增長抵消了盈利下降的負面影響，重申該股為行業首選，給予增持評級，目標價為 HKD40。</p>
<p>摩根士丹利表示，中國人壽第一季度新業務價值增長 76% 表現強勁，顯著優於同行。儘管盈利下降 32%，但業績仍略好於市場預期，業務質量持續改善。維持增持評級，目標價為 HKD37.9。（廣告/用户）（香港股票報價延遲至少 15 分鐘。空頭數據截至 2026-04-29 16:25。）</p>
<p>本文由 AI 自動翻譯，中文版本應視為權威版本。AASTOCKS.com Limited 不保證其準確性或完整性，並對因使用此翻譯而產生的任何損害或損失不承擔任何責任。</p>

中國人壽

<p>中國人壽的股票在發佈第一季度業績後上漲超過 5%，儘管淨利潤同比下降 32.3%，降至 195.05 億元人民幣。該公司報告的營業收入下降 15.3%，但總保費收入增長 1.1%。值得注意的是，新業務價值激增 75.5%。來自摩根大通和摩根士丹利的分析師對新業務價值的強勁增長表示讚賞，維持了超配評級，目標價格分別為 40 港元和 37.9 港元</p>

<p>CHINA LIFE (02628.HK) +1.280 (+4.672%)  Short selling $497.98M; Ratio 30.304%  opened 4.01% higher today and once peaked at HKD29.18. It is now trading at HKD28.84, up 5.26%, with 38.4531 million shares traded, involving HKD1.107 billion.</p>
<div class="lb-trans"><p>中國人壽 (02628.HK) +1.280 (+4.672%) 空頭頭寸 $497.98M; 比率 30.304% 今天開盤上漲 4.01%，一度達到 HKD29.18。目前交易價格為 HKD28.84，上漲 5.26%，成交量為 3845.31 萬股，涉及金額為 11.07 億港元。</p>
</div><p>After market close yesterday, CHINA LIFE announced its first-quarter results. Net profit attributable to shareholders of the parent company amounted to RMB19.505 billion, down 32.3% YoY, with basic EPS of RMB0.69. During the period, operating revenue declined 15.3% YoY to RMB93.291 billion. Total premium income rose 1.1% YoY to RMB358.478 billion. New business value surged 75.5%.</p>
<div class="lb-trans"><p>在昨日市場收盤後，中國人壽公佈了第一季度業績。歸屬於母公司股東的淨利潤為人民幣 195.05 億元，同比下降 32.3%，基本每股收益為人民幣 0.69。在此期間，營業收入同比下降 15.3%，為人民幣 932.91 億元。總保費收入同比增長 1.1%，達到人民幣 3584.78 億元。新業務價值激增 75.5%。</p>
</div><p>JPM stated that the strong growth in new business value offset the negative impact of the earnings decline, reiterating the stock as a sector top pick with an Overweight rating and a TP of HKD40.</p>
<div class="lb-trans"><p>摩根大通表示，新業務價值的強勁增長抵消了盈利下降的負面影響，重申該股為行業首選，給予增持評級，目標價為 HKD40。</p>
</div><p>M Stanley said CHINA LIFE's 1Q new business value growth of 76% was robust and significantly outperformed peers. Despite a 32% drop in earnings, results were still slightly better than market expectations, with continued improvement in business quality. It maintained an Overweight rating with a TP of HKD37.9. (ad/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-29 16:25.)</p>
<div class="lb-trans"><p>摩根士丹利表示，中國人壽第一季度新業務價值增長 76% 表現強勁，顯著優於同行。儘管盈利下降 32%，但業績仍略好於市場預期，業務質量持續改善。維持增持評級，目標價為 HKD37.9。（廣告/用户）（香港股票報價延遲至少 15 分鐘。空頭數據截至 2026-04-29 16:25。）</p>
</div><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p>
<div class="lb-trans"><p>本文由 AI 自動翻譯，中文版本應視為權威版本。AASTOCKS.com Limited 不保證其準確性或完整性，並對因使用此翻譯而產生的任何損害或損失不承擔任何責任。</p>
</div>

CHINA LIFE  Jumps Over 5% Post-Results; M Stanley and JPM Cite Strong 1Q New Business Value Growth

AASTOCKS News

摩根士丹利

摩根大通

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

中國人壽在業績公佈後股價上漲超過 5%；摩根士丹利和摩根大通指出其第一季度新業務價值增長強勁